Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis

Bone

Volumn 33, Issue 1, 2003, Pages 150-158

  Ravn, P ^a,c   Thompson, Desmond E ^b   Ross, Philip D ^b   Christiansen, C ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b MERCK RESEARCH LABORATORIES   (United States)

^c CCBR   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; OSTEOCALCIN; PEPTIDE DERIVATIVE; PLACEBO;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION FUNCTION; DIAGNOSTIC ACCURACY; DRUG EFFECT; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIP; HUMAN; NORMAL HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; ROC CURVE; SPINE; TREATMENT OUTCOME;

EID: 0043125769     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(03)00168-6     Document Type: Article

References (26)

1. Bjarnason N.H., Christiansen C. Early response in biochemical markers predicts long-term response in bone mass during HRT in early postmenopausal women. Bone. 26:2000;561-569.
2. Bjarnason N.H., Bjarnason K., Hassager C., Christiansen C. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone. 20:1997;151-155.
3. Chesnut C.H. 3rd, Bell N.H., Clark G.S., Drinkwater B.L., English S.C., Johnson C.C. Jr, et al. Hormone replacement therapy in postmenopausal women urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density . Am J Med. 102:1997;29-37.
4. Christgau S., Rosenquist C., Alexandersen P., Bjarnason N.H., Ravn P., Fledelius C., et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem. 44:1998;2290-2300.
5. Garnero P., Shih W.J., Gineyts E., Karpf D.B., Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 79:1994;1693-1700.
6. Garnero P., Darte C., Delmas P.D. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone. 24:1999;603-609.
7. Gonnelli S., Cepollaro C., Pondrelli C., Martini S., Monaco R., Gennari C. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Miner Res. 12:1997;624-631.
8. Greenspan S.L., Parker R.A., Ferguson L., Rosen H.N., Maitland-Ramsey L., Karpf D.B. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women a randomized clinical trial . J Bone Miner Res. 13:1998;1431-1438.
9. Ravn P., Christensen J.O., Baumann M., Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment prediction of bone mass changes during treatment . Bone. 22:1998;559-564.
10. Ravn P., Clemmesen B., Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone. 24:1999;237-244.
11. Ravn P., Hosking D., Thompson D., Cizza G., Wasnich R.D., McClung M., et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the Early Postmenopausal Intervention Cohort Study. J Clin Endocrinol Metab. 84:1999;2363-2368.
12. Riis B.J., Overgaard K., Christiansen C. Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy. Osteoporos Int. 5:1995;276-280.
13. Rosen C.J., Chesnut C.H. 3rd, Mallinak N.J.J. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. Clin Endocrinol Metab. 82:1997;1904-1910.
14. Delmas P.D., Hardy P., Garnero P., Dain M.-P. Monitoring individual response to hormone replacement therapy with bone markers. Bone. 26:2000;553-560.
15. Who are candidates for prevention and treatment of osteoporosis? Osteoporos Int. 7:1997;1-6.
16. Genant H.K., Engelke K., Fuerst T., Gluer C.C., Grampp S., Harris S.T., et al. Noninvasive assessment of bone mineral and structure state of the art . J Bone Miner Res. 11:1996;707-730.
17. Hosking D., Chilvers C.E.D., Christiansen C., Ravn P., Wasnich R., Ross P., et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med. 338:1998;485-492.
18. Ravn P., Bidstrup M., Wasnich R.D., Davis J.W., McClung M.R., Balske A., et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss four-year results from the Early Postmenopausal Intervention Cohort Study. A randomized, controlled trial . Ann Intern Med. 131:1999;935-942.
19. Rosenquist C., Qvist P., Bjarnason N., Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem. 41:1995;1439-1445.
20. Minisola S., Rosso R., Romagnoli E., D'Erasmo E., Manfredi G., Damiani C., et al. Serum osteocalcin and bone mineral density at various skeletal sites a study performed with three different assays . J Lab Clin Med. 129:1997;422-429.
21. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem. 40:(11 Pt 1):1994;2022-2025.
22. Hanson D.A., Weis M.A., Bollen A.M., Maslan S.L., Singer F.R., Eyre D.R. A specific immunoassay for monitoring human bone resorption quantitation of type I collagen cross-linked N-telopeptides in urine . J Bone Miner Res. 7:1992;1251-1258.
23. Gertz B.J., Shao P., Hanson D.A., Quan H., Harris S.T., Genant H.K., et al. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res. 9:1994;135-142.
24. Christgau S., Bitsch-Jensen O., Bjarnason N.B., Henriksen E.G., Qvist P., Alexandersen P., et al. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone. 26:2000;505-511.
25. Bjarnason N.H., Sarkar S., Duong T., Mitlak B., Delmas P.D., Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int. 12:2001;922-930.
26. Garnero P., Hausherr E., Chapuy M.C., Marcelli C., Grandjean H., Muller C., et al. Markers of bone resorption predict hip fracture in elderly women the EPIDOS prospective study . J Bone Miner Res. 11:1996;1531-1538.